阅读说明：本技术 一种从老鹰茶中提取分离呋喃酮类化合物的方法及其应用 (Method for extracting and separating furanone compounds from Litsea coreana and application thereof ) 是由 肖世基 方亦可 王一名 孙成新 董敏健 张涛 杨建文 于 2021-08-23 设计创作，主要内容包括：本申请公开了分离提取技术领域中一种从老鹰茶中提取分离呋喃酮类化合物的方法,包括回流提取、溶剂萃取、硅胶中压柱色谱分离以及高效液相色谱分离,最终得到呋喃酮类化合物,结构式如下所示,MTT活性测试显示该呋喃酮类化合物对人胰腺癌SW1990细胞具有很强的细胞毒活性,其IC50为2.520μg/mL。AO/PI双重荧光染色高剂量组晚期凋亡细胞数目明显增多,表明该呋喃酮类化合物能够促进人胰腺癌SW1990细胞凋亡,可用于制备潜在抗癌药物。(The application discloses a method for extracting and separating furanone compounds from Litsea Coreana in the technical field of separation and extraction, which comprises reflux extraction, solvent extraction, silica gel medium pressure column chromatography separation and high performance liquid chromatography separation to finally obtain the furanone compounds, the structural formula is shown as follows, MTT activity test shows that the furanone compound has strong cytotoxic activity on SW1990 human pancreatic cancer cells, and the IC50 of the furanone compound is 2.520 mu g/mL. The number of advanced apoptotic cells in a high-dose group subjected to AO/PI double fluorescent staining is obviously increased, which shows that the furanone compound can promote the apoptosis of SW1990 cells in human pancreatic cancer, and can be used for preparing potential anticancer drugs.)

1. A method for extracting and separating furanone compounds from Litsea coreana is characterized in that the furanone compounds have the chemical structural formula as follows:

the extraction and separation steps are as follows:

1) taking overground parts of the glede tea, drying and crushing the overground parts, performing reflux extraction for 3-4 times by using methanol with the concentration of 90%, performing extraction for 3-4 hours each time, combining extracting solutions obtained by filtering after extraction for each time, and performing reduced pressure concentration to obtain a methanol extract;

2) dispersing the methanol extract obtained in the step 1) in water, then sequentially extracting for 3-4 times by using petroleum ether, ethyl acetate and n-butyl alcohol, and concentrating under reduced pressure to obtain extract of each extraction part;

3) separating the part of the extract extracted by the ethyl acetate in the step 2) by column chromatography, and performing gradient elution by using petroleum ether-ethyl acetate according to the volume ratio of 9:1, 4:1, 3:2, 2:3, 1:4 and 1:0 to divide the extract into 6 components;

4) analyzing the part of the petroleum ether and the ethyl acetate which are 3:2 in the step 3) by using HPLC, merging, separating by using column chromatography again, and performing gradient elution by using the petroleum ether and the ethyl acetate according to the volume ratio of 9:1, 4:1, 3:2, 2:3, 1:4 and 1:0 to divide the petroleum ether and the ethyl acetate into 5 subcomponents;

5) mixing the sub-components 2-3 obtained in the step 4) by MCI, removing pigments, and separating again to obtain 10 sub-components;

6) separating the 8 th to 10 th sub-components obtained in the step 5) by using preparative HPLC, and isocratically eluting with methanol with the concentration of 85% -100% to obtain the furanone compounds.

2. The method for extracting and separating furanones from Litsea coreana of claim 1, wherein the furanones are extracted from Litsea coreana by the following steps: in the step 6), the detection wavelength is 210 nm-280 nm, and the flow rate is 2.0m L/min-20 m L/min.

3. The method for extracting and separating furanones from Litsea coreana of claim 2, wherein the furanones are extracted from Litsea coreana by the following steps: and step 6), gradient elution is carried out by using methanol with the concentration of 90-100%.

4. The method for extracting and separating furanones from Litsea coreana of claim 3, wherein the furanones are extracted from Litsea coreana by the following steps: c for chromatographic column in step 6)₁₈10 μm, 10 mm. times.250 mm, and a flow rate of 20 mL/min.

5. Use of furanone compounds extracted by the extraction method according to any one of claims 1 to 4 in the preparation of anticancer drugs.

6. Use of furanone compounds extracted by the extraction method according to any one of claims 1-4 in preparation of anti-pancreatic cancer drugs.

Technical Field

The invention relates to the technical field of separation and extraction, in particular to a method for extracting and separating furanone compounds from Litsea coreana and application thereof.

Background

Tender tips and leaves of Litsea coreana (Litsea coreana L. vl. var. lanuginosa (Migo) Yang et P. H. Huang) belonging to Litsea of Laoyac Lauraceae are herbal tea with homology of medicine and food, widely distributed in Guizhou, Yunnan, Sichuan and the like, and residents in remote mountain villages in Guizhou where water, Xichuan, Xiguan, Meitan, Kaiyang and the like are used for keeping the drinking habit of Litsea coreana. According to the compendium of materia medica, the eagle tea is recorded to have the effects of relieving cough, eliminating phlegm, relieving asthma, relieving summer heat and quenching thirst, and modern researches prove that the eagle tea has the effects of resisting oxidation, reducing sugar, reducing fat, resisting inflammation, resisting bacteria, resisting viruses and the like, and has a larger development and application prospect.

At present, the research on chemical components in the litsea coreana mainly comprises compounds such as flavonoids, polyphenols and stilbene glycosides, or a lignan compound as proposed in Chinese patent CN 108707133A, and a method and application for extracting and separating the lignan compound from the litsea coreana, but no related report on the furanone component with anticancer activity separated from the litsea coreana exists.

Disclosure of Invention

Aiming at the defects of the prior art, the invention designs a method for extracting and separating furanone compounds from Litsea coreana.

One of the purposes of the invention is to provide a method for extracting and separating furanone compounds from Litsea coreana, wherein the furanone compounds have the chemical structural formula as follows:

the extraction and separation steps are as follows:

1) taking overground parts of the glede tea, drying and crushing the overground parts, performing reflux extraction for 3-4 times by using methanol with the concentration of 90%, performing extraction for 3-4 hours each time, combining extracting solutions obtained by filtering after extraction for each time, and performing reduced pressure concentration to obtain a methanol extract;

2) dispersing the methanol extract obtained in the step 1) in water, sequentially extracting for 3-4 times by using petroleum ether, ethyl acetate and n-butyl alcohol, and concentrating under reduced pressure to obtain extract of each extraction part;

3) separating the part of the extract extracted by the ethyl acetate in the step 2) by column chromatography, and performing gradient elution by using petroleum ether-ethyl acetate according to the volume ratio of 9:1, 4:1, 3:2, 2:3, 1:4 and 1:0 to divide the extract into 6 components;

4) analyzing the part of the petroleum ether and the ethyl acetate which are 3:2 in the step 3) by using HPLC, merging, separating by using column chromatography again, performing chromatographic separation, and performing gradient elution by using the petroleum ether and the ethyl acetate according to the volume ratio of 9:1, 4:1, 3:2, 2:3, 1:4 and 1:0 to divide the petroleum ether and the ethyl acetate into 5 sub-components;

5) mixing the sub-components 2-3 obtained in the step 4) by MCI, removing pigments, and separating again to obtain 10 sub-components;

6) separating the 8 th to 10 th sub-components obtained in the step 5) by preparative HPLC, detecting the wavelength of 210nm to 280nm, the flow rate of 2.0mL/min to 20mL/min, and isocratically eluting with methanol with the concentration of 85 percent to 100 percent to obtain the furanone compounds.

Further, the detection wavelength in the step 6) is 210 nm-280 nm, and the flow rate is 2.0 mL/min-20 mL/min.

Further, methanol with the concentration of 90-100% is used for gradient elution in the step 6).

Further, the column C in step 6)₁₈10 μm, 10 mm. times.250 mm, and a flow rate of 20 mL/min.

The method extracts furanone components with anticancer activity from the litsea coreana for the first time, and the provided preparation method has the advantages of simple process, controllability of the separation method, good reproducibility, low cost and simple operation, and is suitable for popularization and application.

The invention also aims to provide the application of the furanone compound extracted by the extraction method in preparing anti-cancer drugs.

The invention also aims to provide the application of the furanone compounds extracted by the extraction method in preparing anti-pancreatic cancer drugs.

The chemical structure of the furanone compound provided by the invention is¹HNMR、¹³The identification of the CNMR spectroscopy technique, which is identified by reference to the relevant literature, has the following physicochemical constants and spectral characteristics. The nuclear magnetic data are shown in Table 1.

Table 1: nuclear magnetic data for the Compound (400/100MHz, CDCl)₃)

The data are consistent with (4S,5S, Z) -3-decylidene-4-hydroxy-5-methyllbu-tanolide data reported in the literature (Phytochemistry Letters,2015,11:32-36.), and the compound is identified as (4S,5S, Z) -3-decylidene-4-hydroxy-5-methyllbu-tanolide by combining mass spectrum data.

The invention takes the litsea coreana as the raw material, and adopts the method of solvent extraction combined with column chromatography to obtain the furanone compound, and pharmacological experiments show that the furanone compound has better anticancer activity.

Drawings

FIG. 1 shows the preparation of furanones of the present invention¹H-NMR chart;

FIG. 2 shows the preparation of furanones of the present invention¹³C-NMR chart;

FIG. 3 is a graph comparing the cytotoxic effects of furanones of the present invention on SW 1990;

FIG. 4 is a schematic diagram of the detection of SW1990 apoptosis caused by furanone compounds by AO/PI double staining method.

Detailed Description

The following is further detailed by way of specific embodiments:

the chemical structural general formula of the furanone compound is as follows:

example 1:

the method for extracting and separating the furanone compounds from the litsea coreana comprises the following steps:

1) taking 17.81kg of Litsea Coreana leaf from Litsea Coreana Hayata, drying, pulverizing, extracting with 90% methanol under reflux for 3 times, each time for 3-4 h, and concentrating the extractive solution under reduced pressure to obtain 2020g of methanol extract;

2) dispersing the methanol extract in the step 1) in water, then sequentially extracting with petroleum ether, ethyl acetate and n-butanol for 3 times, and concentrating each extraction part under reduced pressure to obtain each extraction part extract, wherein 889g of the ethyl acetate extraction part extract;

3) separating the ethyl acetate part extract in the step 2) by silica gel medium-pressure column chromatography, and performing gradient elution by using petroleum ether-ethyl acetate according to the volume ratio of 9:1, 4:1, 3:2, 2:3, 1:4 and 1:0 to obtain 6 components Fr.1-Fr.6;

4) separating the 3 rd component Fr.3 (also petroleum ether: ethyl acetate: 3:2 part) in the step 3) by silica gel medium-pressure column chromatography, eluting by using petroleum ether-ethyl acetate in a gradient manner according to the volume ratio of 9:1, 4:1, 3:2, 2:3, 1:4 and 1:0, and dividing the eluate into 5 subfractions Fr.5.1-Fr.5.5;

5) using MCI to mix the Fr.5.2 subfraction obtained in the step 4), removing pigment, and separating again to obtain 10 subfractions Fr.5.2.1-Fr.5.2.10;

6) separating the Fr.5.2.10 subfractions obtained in 5) by preparative HPLC, eluting with 90% -100% methanol gradient, and eluting the chromatographic column with C18, 10 μm, 10mm × 250mm, at a flow rate of 20mL/min to obtain 20 subfractions Fr.5.2.10.1-Fr.5.2.10.20; separating the Fr.5.2.10.12 subfraction by preparative HPLC eluting with a 90% methanol gradient and using C as column₁₈Eluting at 5 μm, 10mm × 250mm, and flow rate of 3mL/min to obtain the furanone compound.

The chemical structure of the furanone compound extracted in the example 1 is subjected to¹HNMR、¹³Identification of the CNMR spectroscopy technique is shown in fig. 1 and 2.

Example 2:

research on effect of furanone compounds on SW1990 cell line of human pancreatic cancer

(1) MTT method for detecting cytotoxicity of furanone compounds on SW1990 cell line of human pancreatic cancer:

selecting human pancreatic cancer SW1990 cells in logarithmic growth phase, and adjusting cell concentration to 3 × 10 with culture solution containing 10% fetal calf serum⁴one/mL, 100. mu.L per well, was seeded into 96-well flat-bottomed cell culture plates and placed at 37 ℃ in 5% CO₂After 12h of incubation in an incubator, 100. mu.L of samples were added, the concentration of the samples was 0.1, 0.5, 1, 5, 10, 20. mu.g/mL, 5 duplicate wells were set, 5% CO at 37 ℃ and₂the cultivation was continued in the incubator for 48 h. Then 20. mu.L of MTT solution (5mg/mL) was added to each well and incubation was continued for 3h, and the supernatant was discarded. Finally, 150. mu.L of DMSO was added to each well, the crystals were sufficiently dissolved by low-speed shaking for 20min, and the absorbance value was measured at a wavelength of 490nm, and the cell viability, which is the absorbance value of the experimental group/the absorbance value of the control group x 100%, was calculated. One-way anova analyzed the statistical difference between the drug-treated groups and the control group. The results showed that furanones have excellent antitumor activity (. about.. about.P represents P)<0.001, statistically significant), and is concentration gradient dependent. The IC50 value of furanones in SW1990 human pancreatic cancer cell line was calculated to be 2.520. mu.g/mL, and the experimental results are shown in FIG. 3.

(2) Acridine orange and pyridine iodide (AO/PI) double staining method for detecting influence of furanone compounds on apoptosis of SW1990 cell line of pancreatic cancer

Selecting human pancreatic cancer SW1990 cells in logarithmic growth phase, and adjusting cell concentration to 10 × 10 with culture solution containing 10% fetal calf serum⁴one/mL, 1mL per well, was seeded into 24-well flat-bottomed cell culture plates and placed at 37 ℃ in 5% CO₂Culturing in an incubator for 12 h. The supernatant was aspirated, and 500. mu.L of sample was added at concentrations of 0, 0.5, 2. mu.g/mL, 5% CO at 37 ℃ C₂The incubator continues to culture for 24 h. The supernatant was aspirated, cells were washed once with PBS and added to each well50 mu L of PBS, 50 mu L of AO (100 mu g/mL) and 50 mu L of PI (100 mu g/mL) are placed in a pore plate, incubated for 10min in a dark place at room temperature and observed and photographed under a fluorescence microscope, the experimental result is shown in figure 4, the control group has no obvious apoptotic cells, the high-dose group can be seen to have obvious late apoptotic cell increase, the cell nucleus is orange red due to PI staining, the cell nucleus is concentrated and biased, and the furanone compound can promote the apoptosis of SW1990 cells in human pancreatic cancer and can be used for preparing potential anticancer drugs.

The foregoing is merely an example of the present invention and common general knowledge of known specific structures and features of the embodiments is not described herein in any greater detail. It should be noted that, for those skilled in the art, without departing from the structure of the present invention, several changes and modifications can be made, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicability of the patent. The scope of the claims of the present application shall be determined by the contents of the claims, and the description of the embodiments and the like in the specification shall be used to explain the contents of the claims.